Back to Dashboard
AGIO · Healthcare

Agios Pharmaceuticals Inc

USA Healthcare Filing: 2026-06-30
21/100
Smart-money confidence
Bottom band — money moving out

1 member of Congress bought

Stocks scoring 25–45 beat the S&P 500 45.3% of the time over the next three months, since 2015. How we measured this →

5
hedge funds
hold it · 1 new, 4 added
1
in Congress
traded it in the past year · 1 bought, 0 sold
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s.  ·  how the score works Consensus buy — 2 of 3 sources positive →
Market cap
$1.8B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About AGIOS PHARMACEUTICALS INC

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and…

Who's behind the signal
Every informed buyer we can see on AGIO, across all three feeds.
Hedge funds · 5
Point72 (Steve Cohen) New position
D.E. Shaw & Co Increased +16%
Citadel Advisors Increased +18%
AQR Capital Management Increased +1780%
Congress · 2
Insiders
No significant Form 4 insider activity in the window.
Congressional trades · 6 on record
Disclosures from 2024-01-24 to 2026-08-20
Trade date Member Chamber Action Amount
2026-08-20 Gilbert Ray Cisneros, Jr. · D-CA House Bought $1,001 - $15,000
2026-03-03 Gilbert Ray Cisneros, Jr. · D-CA House Bought $1,001 - $15,000
2025-12-11 Gilbert Ray Cisneros, Jr. · D-CA House Bought $1,001 - $15,000
2025-04-17 Gilbert Ray Cisneros, Jr. · D-CA House Bought $1,001 - $15,000
2025-01-29 Gilbert Ray Cisneros, Jr. · D-CA House Bought $1,001 - $15,000
2024-01-24 Josh Gottheimer · D-NJ House Bought $1,001 - $15,000
Not a model pick — but on our radar. AGIOS PHARMACEUTICALS INC isn't in the top-10 model right now, but 5 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
5
Investors
1
New positions
4
Increasing
0
Decreasing
0
Unchanged
Price History
Loading price data...
Ctrl/⌘ + scroll or pinch to zoom · drag to measure · double-click to reset Pinch to zoom · drag sideways to move through time
A member of Congress bought A member sold
Return: High: Low:

Markers sit on the transaction date the member disclosed, snapped to the nearest close on the chart. They are not the date the public found out — that came later, and the gap is its own page. Every marker is listed by name in the table above.

Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Portfolio Allocation
How much of each investor's portfolio is allocated to AGIOS PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell AGIOS PHARMACEUTICALS INC or any security.

订阅每周更新

我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费,直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订 · 隐私